Phase II study of eribulin mesylate in patients (pts) with advanced soft tissue sarcoma (STS).
Yoichi Naito
Honoraria - Eisai
Akira Kawai
Expert Testimony - Eisai
Nobuhito Araki
No relevant relationships to disclose
Toshifumi Ozaki
Honoraria - Eisai
Hideshi Sugiura
No relevant relationships to disclose
Yasuo Yazawa
No relevant relationships to disclose
Hideo Morioka
Honoraria - Eisai
Research Funding - Eisai
Akihiko Matsumine
No relevant relationships to disclose
Masahide Hiraiwa
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
Shun Asami
Employment or Leadership Position - Eisai
Honoraria - Eisai
Kazuo Isu
Consultant or Advisory Role - Eisai